Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$159.62
-4.6%
$174.59
$130.96
$182.89
$282.63B0.585.00 million shs10.72 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$146.14
-0.5%
$155.26
$143.13
$175.97
$352.17B0.537.73 million shs6.18 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$131.20
+0.4%
$126.41
$99.14
$133.10
$332.33B0.386.51 million shs7.76 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.40
+0.6%
$26.96
$25.20
$40.37
$143.83B0.6134.12 million shs46.53 million shs
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%-4.08%-12.28%-2.91%-1.35%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.01%-1.20%-7.61%-8.38%-10.13%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+0.01%+4.31%-0.55%+8.59%+15.67%
Pfizer Inc. stock logo
PFE
Pfizer
+0.08%-2.31%-8.47%-7.54%-34.25%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.9759 of 5 stars
3.43.04.23.93.72.52.5
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.935 of 5 stars
3.23.04.23.93.82.51.9
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.6562 of 5 stars
2.33.03.34.13.32.51.9
Pfizer Inc. stock logo
PFE
Pfizer
4.9767 of 5 stars
3.23.04.24.83.01.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.77
Moderate Buy$176.0810.31% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.46
Hold$175.8620.33% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.58
Moderate Buy$131.330.10% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.3343.04% Upside

Current Analyst Ratings

Latest ABBV, MRK, JNJ, and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/26/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$142.00 ➝ $143.00
4/18/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$169.00 ➝ $170.00
4/18/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$168.00 ➝ $167.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$180.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$181.00 ➝ $175.00
4/15/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/8/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$140.00 ➝ $143.00
4/5/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
(Data available from 4/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$54.32B5.20$15.82 per share10.09$5.78 per share27.62
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$85.16B4.14$13.67 per share10.69$28.57 per share5.12
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$60.12B5.53$3.04 per share43.13$14.85 per share8.84
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.46$2.98 per share8.53$15.81 per share1.61

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.86B$3.3747.3713.162.038.95%162.28%14.62%7/25/2024 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$35.15B$16.049.1113.372.4145.26%36.43%15.01%7/18/2024 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$365M$0.90145.7813.211.703.76%14.15%5.24%8/6/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3670.569.171.143.62%10.88%4.91%5/1/2024 (Confirmed)

Latest ABBV, MRK, JNJ, and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/A-$0.57N/AN/AN/A  
4/26/2024Q1 24
AbbVie Inc. stock logo
ABBV
AbbVie
$2.26$2.31+$0.05$3.85$11.93 billion$12.31 billion    
4/25/2024Q1 2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$1.94$2.07+$0.13$2.27$15.21 billion$15.78 billion    
4/16/2024Q1 24
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.64$2.71+$0.07$3.22$21.39 billion$21.38 billion    
2/2/202412/31/2023
AbbVie Inc. stock logo
ABBV
AbbVie
$2.76$2.79+$0.03$5.12$14.02 billion$14.30 billion    
2/1/2024Q4 2023
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.09$0.03+$0.12$0.54$14.49 billion$14.63 billion    
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.203.88%+7.84%183.98%52 Years
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.763.26%+5.70%29.68%63 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.082.35%+6.08%342.22%13 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.61%+2.57%466.67%15 Years

Latest ABBV, MRK, JNJ, and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
4/16/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.243.36%5/20/20245/21/20246/4/2024
2/15/2024
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.553.54%4/12/20244/15/20245/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
5.02
0.87
0.76
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.38
1.16
0.91
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.89
1.25
1.00
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.09%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.77 billionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
131,9002.41 billion2.41 billionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
72,0002.53 billion2.53 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

MRK, ABBV, PFE, and JNJ Headlines

SourceHeadline
The Motley Fool: Pfizer offers a pfat 6.4% dividendThe Motley Fool: Pfizer offers a pfat 6.4% dividend
dallasnews.com - April 28 at 2:54 PM
Principle Wealth Partners LLC Sells 65,121 Shares of Pfizer Inc. (NYSE:PFE)Principle Wealth Partners LLC Sells 65,121 Shares of Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 28 at 2:19 PM
5 Of The Highest Yielding Blue Chip Stocks To Buy Now5 Of The Highest Yielding Blue Chip Stocks To Buy Now
247wallst.com - April 28 at 7:45 AM
3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street
fool.com - April 28 at 5:50 AM
Pfizer (NYSE:PFE) Stock Price Up 0.3%Pfizer (NYSE:PFE) Stock Price Up 0.3%
americanbankingnews.com - April 28 at 3:18 AM
Pfizer Inc. (NYSE:PFE) Receives Consensus Rating of "Hold" from AnalystsPfizer Inc. (NYSE:PFE) Receives Consensus Rating of "Hold" from Analysts
americanbankingnews.com - April 28 at 2:28 AM
Pfizer (NYSE:PFE) Sets New 12-Month Low at $25.20Pfizer (NYSE:PFE) Sets New 12-Month Low at $25.20
americanbankingnews.com - April 28 at 1:52 AM
Pfizer Inc. (PFE)Pfizer Inc. (PFE)
finance.yahoo.com - April 27 at 11:37 PM
Pfizer gets FDA approval for hemophilia B gene therapy BeqvezPfizer gets FDA approval for hemophilia B gene therapy Beqvez
msn.com - April 27 at 11:37 PM
PFG Investments LLC Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)PFG Investments LLC Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 27 at 10:17 PM
3 Dividend Stocks to Buy and Hold for the Next Decade3 Dividend Stocks to Buy and Hold for the Next Decade
fool.com - April 27 at 7:15 AM
7 Dividend Stocks to Buy Now for Steady Returns in Any Market7 Dividend Stocks to Buy Now for Steady Returns in Any Market
investorplace.com - April 27 at 6:00 AM
Pfizer’s First Gene Therapy Gets Approval for Clotting DisorderPfizer’s First Gene Therapy Gets Approval for Clotting Disorder
bloomberg.com - April 26 at 10:34 PM
Pfizer (NYSE:PFE) Notches Up on New FDA ApprovalPfizer (NYSE:PFE) Notches Up on New FDA Approval
msn.com - April 26 at 10:34 PM
Stanley Laman Group Ltd. Buys 44,722 Shares of Pfizer Inc. (NYSE:PFE)Stanley Laman Group Ltd. Buys 44,722 Shares of Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 26 at 9:14 PM
What Factors Will Drive Pfizers Q1 Performance?What Factors Will Drive Pfizer's Q1 Performance?
forbes.com - April 26 at 5:34 PM
Pfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, UniqurePfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, Uniqure
finance.yahoo.com - April 26 at 5:34 PM
FDA Green Lights Pfizers Gene Therapy For Rare Bleeding Disorder HemophiliaFDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
finance.yahoo.com - April 26 at 5:34 PM
Pfizer (NYSE:PFE) Sets New 52-Week Low at $25.20Pfizer (NYSE:PFE) Sets New 52-Week Low at $25.20
marketbeat.com - April 26 at 2:35 PM
GSK sues Pfizer and BioNTech over mRNA billionsGSK sues Pfizer and BioNTech over mRNA billions
thepharmaletter.com - April 26 at 12:33 PM
Pfizer Gains as Gene Therapy Wins FDA NodPfizer Gains as Gene Therapy Wins FDA Nod
baystreet.ca - April 26 at 12:33 PM
FDA approves Pfizer’s gene therapy Beqvez for adults with hemophilia BFDA approves Pfizer’s gene therapy Beqvez for adults with hemophilia B
thepharmaletter.com - April 26 at 12:33 PM
Gear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key MetricsGear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key Metrics
zacks.com - April 26 at 10:21 AM
Pfizer Receives FDA Approval for Bleeding Disorder TreatmentPfizer Receives FDA Approval for Bleeding Disorder Treatment
barrons.com - April 26 at 9:35 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Merck & Co., Inc. logo

Merck & Co., Inc.

NYSE:MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.